What the business is, and whether it's a good one at a fair price.
Operates an integrated diagnostic services network under a hub-and-spoke model, selling pathology and radiology tests to retail and corporate customers across 6 states. The network has grown from 81 to 162 centers over five years, supported by a workforce of over 3,500 employees. Pathology and radiology contribute roughly equally to revenue, with a wellness segment growing around 30% year-on-year layered on top. Q4 FY26 revenue per patient was INR 1,808 and revenue per test was INR 488, with retail wellness realisations at INR 2,500 versus INR 2,000 for corporate customers. Hyderabad is the largest and most mature cluster, growing around 20% year-on-year, while Bangalore (with a Bannerghatta flagship featuring PET CT, high-end MRI and cardiac CT), Pune (under the PH Diagnostics brand), and Kolkata are the next priority geographies; new hubs in these markets have broken even within 9-12 months. The company owns and operates all centres directly (no franchise model) and plans 4-5 hubs and 10-12 spokes in FY27, plus an automated lab in Panjagutta, Hyderabad, with advanced genomic testing being introduced as a long-term play. The largest cost lines are other operating expenses (30.9% of revenue) and employee costs (16.1%), while materials — reagents and consumables — are only 11.6% of revenue, reflecting the asset-heavy, knowledge-labour nature of the business.
Measured from the filed financials, judged against its Healthcare Service Provider peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from VIJAYA DIAGNOSTIC CEN LTD's filed financials and exchange disclosures
VIJAYA DIAGNOSTIC CEN LTD is a Healthcare Services company listed on NSE and BSE, trading under the symbol VIJAYA.
Yes. Over the trailing twelve months VIJAYA DIAGNOSTIC CEN LTD reported a net profit of ₹187 Cr on revenue of ₹857 Cr.
Yes. The dividend yield is 0.13% at the current price. It paid out 12% of its profit as dividend in FY26.
Effectively yes. It holds ₹40 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, VIJAYA DIAGNOSTIC CEN LTD ranks 27 of 29 in Healthcare Service Provider — cheaper than 7% of them, against an industry median of 23.2×. This is a position, not a valuation judgement.
On a typical session VIJAYA DIAGNOSTIC CEN LTD moves 1.05% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by VIJAYA DIAGNOSTIC CEN LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.